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Abstract Neuroblastoma is the most common extracra-
nial solid tumor of childhood. While survival rates are high
for localized disease, treatment response remains poor for a
subset of patients with large tumors or disseminated dis-
ease. Thus, there remains much room for improvement in
treatment strategies for this disease. Using in vitro and in
vivo systems, we present glycogen synthase kinase-3b
(GSK-3b) inhibition as a potential mechanism to treat neu-
roblastoma. Using the speciﬁc GSK-3b inhibitor SB415286,
we demonstrate that GSK-3b inhibition decreases the via-
bility of Neuro-2A cells, as determined by cell proliferation
assay and clonogenic survival. Moreover, we show that
GSK-3b inhibition induces apoptosis in neuroblastoma cells,
as determined by Annexin V staining and conﬁrmed with
DAPI staining. Using ﬂow cytometry, we are able to dem-
onstrate that SB415286 induces the accumulation of cells in
the G2/M phase of the cell cycle. Finally, we show that these
in vitro results translate into delayed tumor growth in vivo
using a heterotopic tumor model in nude mice treated with
SB415286. These ﬁndings suggest that GSK-3b is a poten-
tial molecular target for the treatment of neuroblastoma.
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Introduction
Neuroblastoma is an extracranial solid tumor of childhood,
accounting for 7.8% of childhood cancers in the United
States with approximately 650 new cases diagnosed per
year, according to the Surveillance, Epidemiology, and End
Report (SEER). It is a malignancy of the neural crest cells
arising from the adrenal medulla and paraspinal sympa-
thetic ganglia. Neuroblastoma accounts for 8–10% of all
childhood cancers and for approximately 15% of cancer
deaths in children. While localized tumors are often
responsive to chemotherapy, patients with high risk phe-
notypes have long term survival rates of less than 40%
despite multi-modality treatment approaches including
chemotherapy, radical surgery, and radiation therapy [1, 2].
With only modest improvements in the outcomes of this
high risk group during the past few decades, there is clearly
a need for new treatment strategies, potentially represented
by molecular target-directed drugs.
Glycogen synthase kinase 3 beta (GSK-3b) is a ubiq-
uitously expressed multifunctional serine/threonine kinase
[3]. Initially identiﬁed as a kinase and inactivator of
glycogen synthase, it is now known to have over forty
substrates [4] and to regulate a wide range of cellular
functions including differentiation, growth, proliferation,
motility, cell cycle progression, and apoptosis [5]. Aside
from its association with non-insulin dependent diabetes
mellitus, it is highly expressed in the brain and contributes
to neurologic disorders such as Alzheimer’s disease, schizo-
phrenia, and bipolar disorder [6]. Of special interest is the
involvement of GSK-3b in cancer, with data supporting
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DOI 10.1007/s11060-010-0491-3both a role as a tumor suppressor or a tumor promoter, a
discrepancy that depends on cell type and conditions. For
example, the kinase has been shown to inhibit androgen-
receptor stimulated cell growth in prostate cancer, thus
acting as a tumor suppressor [7]. In contrast, GSK-3b is
highly expressed in colorectal cancer [8, 9] and has been
shown to participate in nuclear factor jB( N F jB)-mediated
cell survival in pancreatic cancer [10], thus behaving like a
tumor promoter. Moreover, the kinase has dual functions in
the regulation of cell survival where it can either activate or
inhibit apoptosis [4], further complicating its involvement
in cancer. Therefore, it is important to carefully study
GSK-3b in speciﬁc cell types of interest to determine
whether potential therapeutic gains can best be made from
either the inhibition or activation of this molecular target.
Recent evidence suggests a potential role for GSK-3b
inhibition in the treatment of neuroblastoma. In a B65
neuroblastoma cell line, inhibition of the kinase-induced
cell cycle arrest that corresponded with reduced cell pro-
liferation in vitro [11]. Similarly, beneﬁts of GSK-3b
inhibition have been observed in ovarian [12], pancreatic
[10, 13], glioblastoma [14], and colorectal [8, 9] cancer. In
the present study, we further investigate the potential ben-
eﬁts of GSK-3b inhibition in neuroblastoma and determine
whether these results translate into an in vivo model.
To inhibit GSK-3b we studied the anilinomaleimide
SB415286, which inhibits GSK-3b in an ATP competitive
manner. In previous studies, lithium has been most com-
monly used to investigate the effects of GSK-3b inhibition,
but it is nonspeciﬁc and may produce results due to other
kinase inhibition [15]. In contrast, the small molecule
inhibitor SB415286 is potent and highly speciﬁc [16].
Although much less data has been published using this
drug, it has been shown to elicit responses attributable to
GSK-3b inhibition without affecting other kinases [17].
Thus, it might serve as a better tool to study GSK-3b
function in neuroblastoma. We found that GSK-3b inhi-
bition leads to reduced proliferation and increased apop-
tosis in neuroblastoma cells. Most importantly, we show
for the ﬁrst time that these effects translate into delayed
tumor growth in vivo.
Materials and methods
Cell culture and GSK-3b inhibitor
Neuro-2A mouse neuroblastoma cells were established by
R. J. klebe and F. H. Ruddle from a spontaneous tumor in
albino strain A mice and were obtained from ATCC. The
SK-N-BE (2) neuroblastoma cell line was developed by
J. L. Biedler from a bone marrow biopsy. SK-N-BE (2) was
obtained from ATCC. These cells express high levels of
N-Myc [18, 19]. The SK-N-SH neuroblastoma cell line was
developed by J. L. Biedler from a bone marrow biopsy.
SK-N-SH was obtained from ATCC. These cells are deﬁ-
cient for N-Myc [18, 19]. Cells were maintained in DMEM
with 10% FBS and 1% penicillin/streptomycin (Life
Technologies, Gaithersburg, MD) and were grown in a 5%
CO2 incubator at 37C. SB415286 (3-[(3-Chloro-4-hydroxy-
phenyl)amino]-4-2(nitrophenyl)-(1H-pyrrole-2,5-dione) was
purchased from Tocris biosciences, Ellisville, MO.
Colorimetric cell proliferation assay
Cell proliferation was determined using cell titer 96
Aqueous Non-Radioactive Cell Proliferation Assay reagent
(Promega). The assay was done following the manufac-
turers protocol. Brieﬂy equal numbers of Neuro-2A cells
were plated into different wells of a 96-well plate and were
treated with various concentrations of SB415286 for 24,
48, 72, or 96 h. Cell viability was determined colorimet-
rically by measuring absorbance at 490 nm. Experiments
were done in triplicate and average fold changes relative to
control and standard errors were calculated.
Colony formation assay
Equal amounts of Neuro-2A cells were plated on 6 cm
dishes. After 4–5 h, cells were treated with either DMSO
control or 25 lM SB415286. Colonies were allowed to
form for 10 days after which cells were ﬁxed with 70%
ethanol and stained with 1% methylene blue. Colonies
having greater than 50 cells were counted under a micro-
scope and plotted. Experiments were repeated in triplicate
and means and standard error were calculated.
Apoptosis assays
Apoptosis was measured using Annexin V-APC/propidium
iodide detection kit (BD PharMingen, San Diego, CA)
following the manufacturer’s protocol. Brieﬂy, 10
5 Neuro-
2A cells treated with DMSO or 25 lM SB415286 for 24,
28, 72, or 96 h were incubated with Annexin V-APC/pro-
pidium iodide and analyzed by ﬂow cytometry using a two-
color FACS analysis (BD LSR II). The percentage of cells
staining positive for Annexin V was calculated, and means
and standard error were plotted. Alternatively, apoptosis
was also determined using 40,6-diamidino-2-phenylindole
(DAPI) staining. Neuro-2A cells were grown on slides and
treated with either DMSO or 25 lM SB415286 for 24, 48,
72, or 96 h. After treatment, cells were washed with PBS,
ﬁxed with 4% paraformaldehyde and stained with 5 lg/ml
of DAPI at room temperature for 10 min. Nuclear mor-
phology was observed using a ﬂuorescent microscope
equipped with a digital camera.Apoptosis was quantiﬁedby
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high power ﬁelds (HPF) with apoptotic nuclear morphology
at the single cell level. Mean and standard error were cal-
culated for each time point and treatment group.
Immunoblot analysis
Neuro-2A cells were plated on 10 cm dishes and treated
with DMSO or 25 lM SB415286 for 24, 48, 72, or 96 h.
After 5 days, cells were lysed and harvested using M-PER
mammalian protein extraction reagent (Pierce, Rockford,
IL). Protein concentrations were quantiﬁed using BCA
Reagent (Pierce, Rockford, IL) and equal amounts of
protein (40 lg) were subjected to western immunoblot
analysis using antibodies to beta-catenin (Cell Signaling),
X-linked inhibitor of apoptosis protein (XIAP, BD Trans-
duction Laboratories), and Bcl-2 (Santa Cruz). Antibody to
actin was used to evaluate protein loading in each lane.
Immunoblots were developed using the Western Lighting
Chemiluminescence Plus detection system (PerkinElmer,
Wellesley, MA) according to the manufacturer’s protocol.
Cell cycle analysis
Neuro-2A Cells were plated in 10 cm dishes and treated
with DMSO or 25 lM SB415286 for 24, 48, 72, or 96 h.
Cells were trypsinized, ﬁxed with 70% ethanol, and incu-
bated overnight at -20C. Cells were pelleted and resus-
pended in 200 ll of PBS with 50 ll DNAase-free, RNAase
A, and incubated at 37C for 30 min. Propidium iodide
(750 ll) was added and cells were incubated at room
temperature for 15 min and analyzed by ﬂow cytometry.
The ﬂow data obtained from the samples were then ana-
lysed using the software for cell cycle, Modﬁt LT 3.0. The
average percentages of cells in G1G0 or G2-M phases of
the cell cycle were quantiﬁed and standard error was cal-
culated for three experiments.
Silencing of GSK-3b with shRNA
To identify shRNA sequences that could knockdown GSK-
3b in neuroblastoma cells, we screened ﬁve MISSION
shRNA clones NM_019827.2-1527s1c1 (Sigma–Aldrich,
St. Louis, MO) targeted against the mouse GSK-3b
sequence. MISSION shRNA clones together with packag-
ing and envelope plasmids pUMVC and pCMV-VSV-G
(provided by Sheila Stewart, Washington University), were
transfected into HEK293T packaging cells using Fugene 6.
At 48 h post-transfection, virus-containing media was used
to infect neuroblastoma cells. GFP was used to monitor the
efﬁciency of HEK293T transfection and infection. After
selection with puromycin (1 lg/ml) for 36–48 h, cells were
tested for GSK-3b expression by immunoblotting and then
used for clonogenic survival assays and immunoblot
analyses.
Mice, treatment, and tumor growth delay
All animal procedures used in this study were approved by
the Department of Comparative Medicine (DCM) at
Washington University, and the housing and handling of
animals followed DCM guidelines. 5 9 10
6 Neuro-2A
cells were injected into the right ﬂank of nude mice. Once
tumors were palpable, tumors were measured via calipers
and mice were stratiﬁed into two treatment groups of 5–6
mice representing similar distributions of tumor sizes. Mice
were then treated with DMSO or 1 mg/kg SB415286 i.p.
once daily for 5 consecutive days. Tumor volumes were
followed every day by external caliper measurements.
Tumor volumes for each animal were normalized to the
initial tumor volume at the start of treatment, and the mean
tumor fold increase and standard error was calculated for
each treatment group. The mice on day 6 treatment of
DMSO were euthanized as the tumors were larger than
1000 mm
3 and were not allowed by the animal protocol.
Results
GSK-3b inhibition decreases cell proliferation
in neuroblastoma cell lines
GSK-3b has been described as both a tumor promoter and a
tumor suppressor depending on the cancer cell type [5]. To
elucidate the role of GSK-3b in neuroblastoma, we inves-
tigated how SB415286, a selective GSK-3 inhibitor with Ki
of 31 nmol/l [15], affects cell proliferation in Neuro-2a,
SK-N-SH and SK-N-BE (2). Equal numbers of cells were
plated in a 96 well plate and the following day treated with
concentrations of 0, 1, 2.5, 5, 10, 25, 50 and 100 lM
SB415286 for 24, 48, 72, or 96 h. The plates were read at
96 h using the colorimetric cell proliferation assay by
measuring the absorbance at 490 nm. All three neuro-
blastoma cell lines showed reduction in cell proliferation
after 24 h of treatment with 25 lM SB415286, with a
maximum reduction at 96 h (Fig. 1 a, b, c). This anti-
proliferative effect was dose and time dependent at 25, 50
and 100 lM at 24, 48, 72 and 96 h. These results indicate
that inhibition of GSK-3b by small molecule inhibitors
attenuates neuroblastoma cell proliferation. For further
assays we used 25 lM of SB415286.
GSK-3b inhibition reduces neuroblastoma cell survival
To determine whether GSK-3b inhibition reduces cell
viability and survival of neuroblastoma cells, we performed
J Neurooncol (2011) 104:145–153 147
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determine if cells are undergoing apoptosis, necrosis,
senescence, or mitotic-catastrophe leading to their inability
to multiply and form colonies. Equal numbers of Neuro-
2A, SK-N-SH and SK-N-BE (2) cells were plated on 6 cm
dishes and treated with 25 lM SB415286 or DMSO con-
trol. A signiﬁcant decrease in colony forming units was
observed in all the three neuroblastoma cell lines. Speciﬁc
knockdown of GSK-3b by speciﬁc shRNA in Neuro-2a,
SK-N-SH and SK-N-BE (2) neuroblastoma cells showed
reduced number of colonies compared to cells treated with
control shRNA. These results indicate that inhibition of
GSK-3b in neuroblastoma led to reduced cell viability.
GSK-3b inhibition induces apoptosis in Neuro-2A
One of the many cellular functions of GSK-3b is the reg-
ulation of apoptosis [5]. To determine whether the reduction
in Neuro-2A cell proliferation and cell survival observed
following GSK-3b inhibition could depend in part on the
promotion of apoptosis, we used ﬂow cytometry to stain for
the apoptotic marker Annexin V. Neuro-2A cells were
treated with 25 lM of SB415286 or DMSO for 24, 48, 72,
or 96 h. Cells were stained with Annexin V-APC and pro-
pidium iodide, and then analyzed by ﬂow cytometry.
Apoptotic cells were identiﬁed as those that were Annexin
V positive. Consistent with the cell proliferation assay
(Fig. 1), no signiﬁcant effects on apoptosis were observed
following treatment with SB415286 for 24 h (Fig. 2b).
However, the percentage of cells with apoptotic nuclei
increased from 9 to 16% at 48 h, 6.3 to 10.5% at 72 h, and
5.7 to 12.4% at 96 h, illustrating that apoptosis is promoted
by GSK-3b inhibition in neuroblastoma. To further conﬁrm
that GSK-3b inhibition induced apoptosis in Neuro-2A
cells, we studied the nuclear morphology of cells following
DAPI staining (Fig. 2c). Slides containing Neuro-2A cells
were treated with 25 lM of SB415286 or DMSO for 24, 48,
72, or 96 h and subsequently stained with DAPI. The per-
centage of cells with apoptotic nuclei increased from 5 to
42% at 48 h, 5 to 38% at 72 h, and 3 to 50% at 96 h
(Fig. 2d), conﬁrming the induction of apoptosis following
treatment. Together, these results suggest that the reduced
cell survival induced during GSK-3b inhibition is associ-
ated with increased apoptosis.
GSK-3b reduces the expression of anti-apoptotic
proteins
Neuroblastoma cell proliferation and differentiation is
regulated by the induction of apoptosis [20]. It has been
documented in renal cell carcinoma that GSK-3b may
inhibit apoptosis by inducing the expression of anti-apop-
totic proteins XIAP and Bcl-2 [21]. Immunoblotting was
performed to determine if GSK-3b inhibition-induces
apoptosis in Neuro-2A cells and if so whether XIAP and
Bcl-2 plays a role. GSK-3b in Neuro-2A cells was inhib-
ited either by 25 lM SB415286 or by speciﬁc shRNA to
GSK-3b. The treated cell lysates were probed for XIAP
and Bcl-2 using western immunoblot. Following inhibition
of GSK-3b in Neuro-2A, protein levels of both of XIAP
and Bcl-2 were reduced (Fig. 3a, b). This suggests that
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Fig. 1 GSK-3b inhibition decreases cell proliferation in neuroblas-
toma cell lines. Equal numbers of neuroblastoma cells were plated in
96 well plates and treated with various concentrations of GSK-3b
inhibitor SB415286 for 24, 48, 72 and 96 h. After 5 days, the cell
viability was determined using a colorimetric cell proliferation assay
(Promega). Shown are the absorbance at 490 nm of Neuro-2a (a),
SK-N-SH (b) and SK-N-BE (2) (c)
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123GSK-3b inhibition might induce apoptosis in neuroblas-
toma in part by reducing expression of the anti-apoptotic
proteins XIAP and Bcl-2.
To conﬁrm that SB415286 and speciﬁc shRNA inhibits
GSK-3b function, we studied the protein expression of b-
catenin, a downstream target of GSK-3b. Active GSK-3b
normally phosphorylates b-catenin, leading to its degra-
dation by the ubiquitin–proteasome system. Thus, inhibi-
tion of GSK-3b should induce the accumulation of
b-catenin. b-catenin was stabilized following treatment
with both SB415286 and shRNA speciﬁc to GSK-3b,
conﬁrming inhibition of GSK-3b.
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Fig. 2 GSK-3b inhibition induces cell death and apoptosis in Neuro-
2A. Colony formation assay. a Neuro-2a, SK-N-SH and SK-N-BE (2)
cells were inhibited for GSK-3b either using a small molecule
inhibitor of GSK-3b SB415286 (25 lM) or by a speciﬁc shRNA for
GSK-3b. Equal numbers of cells were plated and were stained with
1% methylene blue after 10–15 days and colonies were counted.
Shown is the bar graph depicting the colony forming units (cfu).
Annexin V staining. b Neuro-2A cells were treated with GSK-3b
inhibitor SB415286 (25 lM) or DMSO for 24, 48, 72 or 96 h. Cells
were stained with Annexin V-APC/propidium iodide and analyzed by
ﬂow cytometry. Shown is the bar graph of average percent of
apoptotic cells for each treatment with SEM from three experiments;
*P\0.05. DAPI staining. c, d Neuro-2A cells were ﬁxed and stained
with DAPI, and apoptotic cells indicated by arrows were counted in
multiple randomly selected ﬁelds. Shown are representative micro-
scopic photographs (c) and a bar graph (d) of average percent of
apoptotic cells vs. total cell number for each treatment with SEM
from three experiments; *P\0.05
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of Neuro-2A cells at G2/M
GSK-3b interacts with proteins that regulate cell cycle
progression, further indicating a role for GSK-3b in cancer
[11]. In fact GSK-3b inhibition can induce G2/M cell cycle
arrest in colon, ovarian, and pancreatic cancer [8, 10, 12,
13]. We therefore investigated the effect of SB415286 on
cell cycle parameters. Neuro-2A cells were treated with
25 lM of SB415286 or DMSO for 24, 48, 72, or 96 h.
Cells were then stained with propidium iodide and ana-
lyzed by ﬂow cytometry. Propidium iodide staining
allowed us to determine the DNA content of the cells,
which provides information on the percentage of cells in
G0G1, S phase, and G2/M. Following GSK-3b inhibition,
the percentage of cells at G2/M increased (from
11.9–21.31%, P = 0.0001) at 24 h, and this effect was
continued at later time points (Fig. 4). There was also a
parallel increase in the percentage of treated cells in the S
phase of the cell cycle as compared to control. Conversely,
the percentage of treated cells in G0G1 decreased by 24 h
after treatment with SB415286 as compared to control
(55.4–40.7%, respectively, P\0.0001). This suggests that
GSK-3b plays a role in cell cycle regulation and that GSK-
3b inhibition induces an accumulation of Neuro-2A cells at
G2/M and in the S phase of the cell cycle.
GSK-3b inhibition induces neuroblastoma tumor
growth delay in mice
To determine the efﬁcacy of GSK-3b inhibition in reducing
growth of neuroblastoma in vivo, a tumor growth assay
was performed. Even though our in vitro results already
showed promising effects of SB415286 in the treatment of
Neuro-2A cells, a signiﬁcant in vivo tumor growth delay
provides stronger evidence of therapeutic potential. Neuro-
2A cells were injected sub cutaneously into the right ﬂanks
of nude mice, and tumor-bearing mice received daily i.p
injections of vehicle or SB415286 for 5 days. Tumor vol-
ume was determined by caliper measurements. As shown
in Fig. 5, GSK-3b inhibition produced a signiﬁcant tumor
growth delay ([2 days), with effects observed by the third
day of treatment.
Discussion
Neuroblastoma, a neoplasm of the sympathetic nervous
system, is the second most common extracranial malignant
tumor of childhood and the most common solid tumor of
infancy. Understanding the molecular biology of neuro-
blastoma could help identify key targets that can efﬁciently
be exploited therapeutically.
GSK-3b, a multifaceted kinase that regulates various
cellular pathways, has been a target for drug development
in the treatment of diabetes, Alzheimer’s disease and var-
ious neurological diseases [6], and has also been of interest
to use against various cancers. GSK-3b inhibitors are
reported to have been used against cancers like human
MLL leukemia [20] renal cell carcinoma [22] colorectal
cancers [8] ovarian cancer [12] and prostrate cancer [23].
In the present study we show that inhibition of GSK-3b
either by small molecule inhibitor SB415286 or by a spe-
ciﬁc shRNA decreases the cell viability of a neuroblastoma
cell lines Neuro-2A, SK-N-SH, and SK-N-BE (2) (Figs. 1a,
b, c, 2a). The decreased viability in Neuro-2A cells can be
explained by induction of apoptosis (Figs. 2b, c, d, 3 a, b)
and cell cycle arrest (Fig. 4 a, b).
We further evaluated the effects of GSK-3b inhibition
on cell survival and proliferation in Neuro-2A cancer cells.
It has been reported that inhibition of GSK-3b leading to
increased levels of b-catenin can antagonize NF-jB
activity by stabilizing the b-catenin-p65 complexes that are
transcriptionally active. We show that Neuro-2A cells
treated with SB415286 induces accumulation of b-catenin
compared to untreated controls (Fig. 3a, b), indicating that
GSK-3b inhibition leads to stabilization of b-catenin that
could potentially inactivate NFjB. Inhibition of GSK-3b
leads to suppressed basal NFjB transcriptional activation
of a subset of anti-apoptotic proteins like Bcl-2 and XIAP
in pancreatic cancer cell proliferation [10]. GSK-3b has
paradoxical effects on apoptosis; it inhibits extrinsic death
receptor-mediated apoptosis, but promotes the mitochon-
drial intrinsic apoptotic pathway [24, 25]. XIAP can inhibit
apoptosis by directly binding and inhibiting several casp-
ases [26]. It has been reported that XIAP could inhibit the
promotion of intrinsic apoptosis signaling by GSK-3
XIAP
Bcl-2
Actin
SB415286
β-catenin
+ -
XIAP
Bcl-2
Actin
sh RNA GSK SCR
β-catenin
AB
Fig. 3 GSK-3b inhibition alters the expression of anti-apoptotic
proteins. GSK-3b was inhibited in Neuro-2A cells either by treating
with a small molecule inhibitor of GSK-3b SB415286 (25 lM) or
with a speciﬁc shRNA for GSK-3b. Western blot analysis was
performed to determine the cellular protein levels of b-catenin, XAIP
and Bcl-2. Actin was used to assess protein loading in each lane
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123through binding to GSK-3 [25]. In our present study we
show that inhibition of GSK-3b with SB415286 reduced
Bcl-2 and XIAP proteins in Neuro-2A cancer cells (Fig. 3
a, b) consistent with the promotion of apoptosis. GSK-3b
inhibition either by lithium or SB415286 has been shown
to increase stabilization of anti apoptotic protein Bcl-2 and
decreased amounts of pro-apoptotic protein Bax in normal
hippocampal cells (HT-22). This increase in Bcl-2 pro-
tected the normal hippocampal cells from radiation induced
apoptosis [27].
GSK-3b has been shown to regulate cyclin/cyclin-
dependent kinases (cdk). The activity of cdks determines
cell cycle progression through checkpoints, including the
gap1 (G1), synthesis (S) and G2/M checkpoint eventually
leading to mitosis. In the present study we also found that
Neuro-2A cells, when treated with SB415286, have a
prolonged S phase followed by a G2/M cell cycle arrest
compared to untreated cells. This could be due to regula-
tion of Cdc2 by GSK-3b which was shown to lead to G2/M
arrest in rat B65 neuroblastoma cells.
Recently it has been shown that GSK-3b promotes the
survivalandproliferationofglioblastomacellsbyprotecting
them from apoptosis [14]. In our studies, the small molecule
inhibitor SB415286 repressed the growth of neuroblastoma
intumorgrowthstudiesinmice(Fig. 5).Taken together,the
present data and previous studies indicate that small
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Fig. 4 GSK-3b inhibition induces G2/M accumulation in Neuro-2A.
Neuro-2A cells were treated with GSK-3b inhibitor SB415286
(25 lM) or DMSO and collected after 24, 48, 72 and 96 h,
stained with and PI and analyzed by ﬂow cytometry. Shown are
a representative diagrams of distribution of stained cells and b bar
graph of the average change in the percent G1G0, S-phase and G2M
cells in each treatment with SEM of three experiments; *P\0.05 (h)
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123molecule inhibitors of GSK-3b could, after obtaining the
results of clinical trials, effectively be used to treat
neuroblastoma.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. De Bernardi B, Nicolas B, Boni L, Indolﬁ P, Carli M, Cordero Di
Montezemolo L, Donfrancesco A, Pession A, Provenzi M, di
Cataldo A, Rizzo A, Tonini GP, Dallorso S, Conte M, Gambini C,
Garaventa A, Bonetti F, Zanazzo A, D’Angelo P, Bruzzi P (2003)
Disseminated neuroblastoma in children older than one year at
diagnosis: comparable results with three consecutive high-dose
protocols adopted by the Italian Co-Operative Group for Neuro-
blastoma. J Clin Oncol 21:1592–1601
2. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE,
Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM,
Gerbing RB, Reynolds CP (1999) Treatment of high-risk neu-
roblastoma with intensive chemotherapy, radiotherapy, autolo-
gous bone marrow transplantation, and 13-cis-retinoic acid.
Children’s Cancer Group. N Engl J Med 341:1165–1173
3. Martinez A (2008) Preclinical efﬁcacy on GSK-3 inhibitors:
towards a future generation of powerful drugs. Med Res Rev
28:773–796
4. Jope RS, Johnson GV (2004) The glamour and gloom of glyco-
gen synthase kinase-3. Trends Biochem Sci 29:95–102
5. Luo J (2009) Glycogen synthase kinase 3beta (GSK3beta) in
tumorigenesisandcancerchemotherapy.CancerLett273:194–200
6. Rayasam GV, Tulasi VK, Sodhi R, Davis JA, Ray A (2009)
Glycogen synthase kinase 3: more than a namesake. Br J Phar-
macol 156:885–898
7. Wang L, Lin HK, Hu YC, Xie S, Yang L, Chang C (2004)
Suppression of androgen receptor-mediated transactivation and
cell growth by the glycogen synthase kinase 3 beta in prostate
cells. J Biol Chem 279:32444–32452
8. Shakoori A, Ougolkov A, Yu ZW, Zhang B, Modarressi MH,
Billadeau DD, Mai M, Takahashi Y, Minamoto T (2005)
Deregulated GSK3beta activity in colorectal cancer: its associa-
tion with tumor cell survival and proliferation. Biochem Biophys
Res Commun 334:1365–1373
9. Shakoori A, Mai W, Miyashita K, Yasumoto K, Takahashi Y, Ooi
A, Kawakami K, Minamoto T (2007) Inhibition of GSK-3 beta
activity attenuates proliferation of human colon cancer cells in
rodents. Cancer Sci 98:1388–1393
10. Ougolkov AV, Fernandez-Zapico ME, Savoy DN, Urrutia RA,
Billadeau DD (2005) Glycogen synthase kinase-3beta participates
in nuclear factor kappaB-mediated gene transcription and cell
survival in pancreatic cancer cells. Cancer Res 65:2076–2081
11. Pizarro JG, Folch J, Esparza JL, Jordan J, Pallas M, Camins A
(2009) A molecular study of pathways involved in the inhibition
of cell proliferation in neuroblastoma B65 cells by the GSK-3
inhibitors lithium and SB-415286. J Cell Mol Med 13:3906–
3917
12. Cao Q, Lu X, Feng YJ (2006) Glycogen synthase kinase-3beta
positively regulates the proliferation of human ovarian cancer
cells. Cell Res 16:671–677
13. Ougolkov AV, Fernandez-Zapico ME, Bilim VN, Smyrk TC,
Chari ST, Billadeau DD (2006) Aberrant nuclear accumulation of
glycogen synthase kinase-3beta in human pancreatic cancer:
association with kinase activity and tumor dedifferentiation. Clin
Cancer Res 12:5074–5081
14. Miyashita K, Kawakami K, Nakada M, Mai W, Shakoori A,
Fujisawa H, Hayashi Y, Hamada J, Minamoto T (2009) Potential
therapeutic effect of glycogen synthase kinase 3beta inhibition
against human glioblastoma. Clin Cancer Res 15:887–897
15. Coghlan MP, Culbert AA, Cross DAE, Corcoran SL, Yates JW,
Pearce NJ, Rausch OL, Murphy GJ, Carter PS, Roxbee Cox L,
Mills D, Brown MJ, Haigh D, Ward RW, Smith DG, Murray KJ,
Reith AD, Holder JC (2000) Selective small molecule inhibitors
of glycogen synthase kinase-3 modulate glycogen metabolism
and gene transcription. Chem Biol 7:793–803
16. Forde J, Dale T (2007) Glycogen synthase kinase 3: a key reg-
ulator of cellular fate. Cell Mol Life Sci 64:1930–1944
17. Martinez A, Castro A, Dorronsoro I, Alonso M (2002) Glycogen
synthase kinase 3 (GSK-3) inhibitors as new promising drugs for
diabetes, neurodegeneration, cancer, and inﬂammation. Med Res
Rev 22:373–384
18. Cui H, Hu B, Li T, Ma J, Alam G, Gunning WT, Ding HF (2007)
Bmi-1 is essential for the tumorigenicity of neuroblastoma cells.
Am J Pathol 170:1370–1378
19. Shastry P, Basu A, Rajadhyaksha MS (2001) Neuroblastoma cell
lines—a versatile in vitro model in neurobiology. Int J Neurosci
108:109–126
20. Brown A, Jolly P, Wei H (1998) Genistein modulates neuro-
blastoma cell proliferation and differentiation through induction
of apoptosis and regulation of tyrosine kinase activity and N-myc
expression. Carcinogenesis 19:991–997
21. Bilim V, Ougolkov A, Yuuki K, Naito S, Kawazoe H, Muto A,
Oya M, Billadeau D, Motoyama T, Tomita Y (2009) Glycogen
synthase kinase-3: a new therapeutic target in renal cell carci-
noma. Br J Cancer 101:2005–2014
22. Wensing M, van der Weijden T, Grol R (1998) Implementing
guidelines and innovations in general practice: which interven-
tions are effective? Br J Gen Pract 48:991–997
23. Mazor M, Kawano Y, Zhu H, Waxman J, Kypta RM (2004)
Inhibition of glycogen synthase kinase-3 represses androgen
receptor activity and prostate cancer cell growth. Oncogene
23:7882–7892
24. Beurel E, Jope RS (2006) The paradoxical pro- and anti-apoptotic
actions of GSK3 in the intrinsic and extrinsic apoptosis signaling
pathways. Prog Neurobiol 79:173–189
Days
01234567
F
o
l
d
 
I
n
c
r
e
a
s
e
0
5
10
15
20 DMSO
SB415286
Treatment
Fig. 5 GSK-3b inhibition results in in vivo tumor growth delay.
Neuro-2A (5 9 10
6) were injected in the ﬂank of nude mice and
allowed to grow until palpable. Mice bearing the tumors were treated
with 1 mg/kg GSK-3b inhibitor SB415286 (dark square) or DMSO
(dark circle) as indicated by arrows. Tumor volume was measured
every day for 6 days. The mice on day 6 treatment of DMSO were
euthanized as the tumors were larger than 1000 mm
3 and were not
allowed by the animal protocol
152 J Neurooncol (2011) 104:145–153
12325. Sun M, Meares G, Song L, Jope RS (2009) XIAP associates with
GSK3 and inhibits the promotion of intrinsic apoptotic signaling
by GSK3. Cell Signal 21:1857–1865
26. Deveraux QL, Roy N, Stennicke HR, Van Arsdale T, Zhou Q,
Srinivasula SM, Alnemri ES, Salvesen GS, Reed JC (1998)
IAPs block apoptotic events induced by caspase-8 and
cytochrome c by direct inhibition of distinct caspases. EMBO J
17:2215–2223
27. Yazlovitskaya EM, Edwards E, Thotala D, Fu A, Osusky KL,
Whetsell WO Jr, Boone B, Shinohara ET, Hallahan DE (2006)
Lithium treatment prevents neurocognitive deﬁcit resulting from
cranial irradiation. Cancer Res 66:11179–11186
J Neurooncol (2011) 104:145–153 153
123